Canadian Journal of Anesthesia

, Volume 53, Issue 12, pp 1180–1185 | Cite as

Protective effect of prior administration of magnesium on delayed hyperalgesia induced by fentanyl in rats

  • Alain C. Van Elstraete
  • Philippe Sitbon
  • Jean -Xavier Mazoit
  • Marc Conti
  • Dan Benhamou
Regional Anesthesia and Pain



Magnesium exerts a physiological block of the ion channel on the N-methyl-D-aspartate receptor, and may therefore prevent the induction of central sensitization. The purpose of this study was to assess whether systemic magnesium can prevent long-lasting hyperalgesia induced by sc fentanyl administration in uninjured rats.


Long-lasting hyperalgesia was induced in male Sprague Dawley rats with sc fentanyl (four injections, 60 μg·kg−1 per injection at 15-min intervals). Magnesium sulphate (100 mg·kg−1) was injectedip 30 min prior to the first sc fentanyl injection. Sensitivity to nociceptive stimuli (paw-pressure test) was assessed for several days after injections.


Subcutaneous fentanyl led to delayed hyperalgesia associated with a decrease in the nociceptive threshold lasting two days (35% decrease for the maximum effect). Intraperitoneal magnesium sulphate partially but significantly (P < 0.05) prevented the delayed decrease in the nociceptive threshold following sc administration of fentanyl.


This study shows that magnesium may prevent the delayed and prolonged hyperalgesia following fentanyl administration in rats.


Fentanyl Neuropathic Pain Magnesium Concentration Magnesium Sulphate Morphine Tolerance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

L’effet protecteur de l’administration préalable de magnésium sur l’hyperalgésie secondaire produite par le fentanyl chez le rat



Le magnésium exerce un blocage physiologique du récepteur N-méthyl-D-aspartate, et peut donc prévenir l’induction d’une sensibilisation centrale. Le but de cette étude était de déterminer si l’administration systémique de magnésium pouvait prévenir l’hyperalgésie prolongée induite par le fentanyl sc chez le rat naïf.


Une hyperalgésie prolongée était induite chez le rat mâle Sprague Dawley avec du fentanyl sc (quatre injections, 60 μg·kg−1 par injection à 15 min d’intervalle). Du sulfate de magnésium (100 mg·kg−1) était injecté par voie ip 30 min avant la première injection de fentanyl. La sensibilité aux stimuli nociceptifs (paw-pressure test) était évaluée durant plusieurs jours après les injections.


Le fentanyl a entraîné une hyperalgésie prolongée associée à une diminution du seuil nociceptif durant deux jours (diminution de 35 % de l’effet maximum). L’administration ip de sulfate de magnésium a prévenu partiellement mais significativement (P < 0,05) la diminution du seuil nociceptif secondaire à l’administration sc de fentanyl.


Cette étude démontre que le magnésium peut prévenir l’hyperalgésie secondaire et prolongée après administration de fentanyl chez le rat.


  1. 1.
    Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100: 213–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Laulin JP, Larcher A, Celerier E, Le Moal M, Simonnet G. Long-lasting increased pain sensitivity in rat fol- lowing exposure to heroin for the first time. Eur J Neurosci 1998; 10: 782–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Laulin JP, Celerier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 1999; 89: 631–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Celerier E, Rivat C, Jun Y, et al. Long-lasting hyper- algesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000; 92: 465–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitiza- tion process. J Neurosci 2001; 21: 4074–80.PubMedGoogle Scholar
  6. 6.
    Mao J, Price DD, Mayer DJ. Mechanisms of hyperal- gesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Mayer DJ, Mao J, Holt J, Price DD. Cellular mecha- nisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 1999; 96: 7731–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen L, Huang LY. Sustained potentiation of NMDA receptor-mediated glutamate responses through acti- vation of protein kinase C by a mu opioids. Neuron 1991; 7: 319–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen L, Huang LY. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992; 356: 521–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Mayer DJ, Mao J, Price DD. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain 1995; 61: 365- 74.PubMedCrossRefGoogle Scholar
  11. 11.
    Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiol- ogy and pharmacology. Br J Anaesth 1999; 83: 302- 20.PubMedGoogle Scholar
  12. 12.
    Woolf CJ, Thomson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain and hypersensitivity states. Pain 1991; 44: 293–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111: 409–19.PubMedGoogle Scholar
  15. 15.
    Gentili ME, Mazoit JX, Samii KK, Fletcher D. The effects of a sciatic nerve block on the development of inflammation in carrageenan injected rats. Anesth Analg 1999; 89: 979–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Mochizuki M, Akagi K, Inoue K, Shimamura K. A single dose toxicity study of magnesium sulfate in rats and dogs (Japanese). J Toxicol Sci 1998; 23(Suppl 1): 31–5.PubMedGoogle Scholar
  17. 17.
    Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg 2002; 94: 1263–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Ben-Eliyahu S, 2,Vaccarino AL, Mogil JS, Sternberg WF, Liebeskind JC. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res 1992; 20: 304–8.CrossRefGoogle Scholar
  19. 19.
    Begon S, Pickering G, Eschalier A, Dubray C. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res 2000; 887: 436–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Karasawa S, Ishizaki K, Goto F. The effect of intra- thecal administration of magnesium sulphate in rats. Anaesthesia 1998; 53: 879–86.PubMedCrossRefGoogle Scholar
  21. 21.
    Takano Y, Sato E, Kaneko T, Sato I. Antihyperalgesic effects of intrathecally administered magnesium sulfate in rats. Pain 2000; 84: 175–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Xiao WH, Bennett GJ. Magnesium suppresses neuro- pathic pain responses in rats via a spinal site of action. Brain Res 1994; 666: 168–72.PubMedCrossRefGoogle Scholar
  23. 23.
    McCarthy RJ, Kroin JS, Tuman KJ, Penn RD, Ivankovich AD. Antinociceptive potentiation and attenuation of tolerance by intrathecal co-infusion of magnesium sulfate and morphine in rats. Anesth Analg 1998; 86: 830–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Oppelt WW, MacIntyre I, Rall DP. Magnesium exchange between blood and cerebrospinal fluid. Am J Physiol 1963; 205: 959–62.PubMedGoogle Scholar
  25. 25.
    Thurnau GR, Kemp DB, Jarvis A. Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulfate: a preliminary report. Am J Obstet Gynecol 1987; 157: 1435–8.PubMedGoogle Scholar
  26. 26.
    Ko SH, Lim HR, Kim DC, Han YJ, Choe H, Song HS. Magnesium sulfate does not reduce postoperative anal- gesic requirements. Anesthesiology 2001; 95: 640–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. Br J Anaesth 2002; 89: 711–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Crosby V, Wilcock A, Corcoran R. The safety and effi- cacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly respon- sive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage 2000; 19: 35–9.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 2006

Authors and Affiliations

  • Alain C. Van Elstraete
    • 1
  • Philippe Sitbon
    • 1
  • Jean -Xavier Mazoit
    • 1
  • Marc Conti
    • 1
  • Dan Benhamou
    • 1
  1. 1.Department of Anesthesiology and Biochemistry Laboratory, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, and the Anesthesia Laboratory UPRES-EA3540Faculté de Médecine du Kremlin-Bicêtre Université Paris-SudLe Kremlin-BicêtreFrance

Personalised recommendations